A recent analysis of a Diabetic Retinopathy Clinical Research Network DME trial revealed that the clinical response following three monthly injections of ranibizumab was predictive of long-term visual outcomes.68 Lazic et al.69 published significant improvements in central foveal thickness and visual acuity in 16 eyes of 15 patients with refractory DME following three anti-VEGF injections who then underwent injection of a corticosteroid. The gene discussed is VEGFA; the disease is diabetic retinopathy.